

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

# OM protein - protein search, using sw model

Run on: January 16, 2003, 16:34:37 : Search time 23.7957 seconds  
(without alignments)  
28.011 Million cell updates/sec

Title: US-09-856-070-25

Perfect score: 23

Sequence: 1 MLRLQ 5

Scoring table: BLOSUM62

Gapop 10 0 Gapext 0 5

Searched: 908470 seqs, 13250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 20000000

Post-processing: Minimum Match 68

Maximum Match 100%

Listing first 45 summaries

Database: A:Genes-L101012.2

```

1: /SUS2/accdata/geneseq/geneseq-emb1/AA1980.DAT:
2: /SUS2/accdata/geneseq/geneseq-emb1/AA1981.DAT:
3: /SUS2/accdata/geneseq/geneseq-emb1/AA1982.DAT:
4: /SUS2/accdata/geneseq/geneseq-emb1/AA1983.DAT:
5: /SUS2/accdata/geneseq/geneseq-emb1/AA1984.DAT:
6: /SUS2/accdata/geneseq/geneseq-emb1/AA1985.DAT:
7: /SUS2/accdata/geneseq/geneseq-emb1/AA1986.DAT:
8: /SUS2/accdata/geneseq/geneseq-emb1/AA1987.DAT:
9: /SUS2/accdata/geneseq/geneseq-emb1/AA1988.DAT:
10: /SUS2/accdata/geneseq/geneseq-emb1/AA1989.DAT:
11: /SUS2/accdata/geneseq/geneseq-emb1/AA1990.DAT:
12: /SUS2/accdata/geneseq/geneseq-emb1/AA1991.DAT:
13: /SUS2/accdata/geneseq/geneseq-emb1/AA1992.DAT:
14: /SUS2/accdata/geneseq/geneseq-emb1/AA1993.DAT:
15: /SUS2/accdata/geneseq/geneseq-emb1/AA1994.DAT:
16: /SUS2/accdata/geneseq/geneseq-emb1/AA1995.DAT:
17: /SUS2/accdata/geneseq/geneseq-emb1/AA1996.DAT:
18: /SUS2/accdata/geneseq/geneseq-emb1/AA1997.DAT:
19: /SUS2/accdata/geneseq/geneseq-emb1/AA1998.DAT:
20: /SUS2/accdata/geneseq/geneseq-emb1/AA1999.DAT:
21: /SUS2/accdata/geneseq/geneseq-emb1/AA2000.DAT:
22: /SUS2/accdata/geneseq/geneseq-emb1/AA2001.DAT:
23: /SUS2/accdata/geneseq/geneseq-emb1/AA2002.DAT:

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	23	100.0	5	AA082040	Human heprecceptor
2	23	100.0	11	AA082039	Human heprecceptor
3	23	100.0	12	AA017959	Integrin binding p
4	23	100.0	12	AA082038	Human heprecceptor
5	23	100.0	12	AA081119	Integrin antagonist
6	23	100.0	12	AA072970	Integrin binding p
7	23	100.0	13	AA082037	Human heprecceptor
8	23	100.0	15	AA082036	Human secreted pro
9	23	100.0	34	AA082035	Human heprecceptor
10	23	100.0	57	AA087003	Human immune/haema

11	23	100.0	73	22	AA082040	Human polypeptide
12	23	100.0	82	22	AA082040	Human cDNA seq ID
13	23	100.0	109	21	AA082040	Human secreted pro
14	23	100.0	111	22	AA082040	Novel human diapo
15	23	100.0	114	21	AA082040	Arabidopsis thalia
16	23	100.0	114	21	AA082040	Arabidopsis thalia
17	23	100.0	115	21	AA082040	Arabidopsis thalia
18	23	100.0	115	21	AA082040	Arabidopsis thalia
19	23	100.0	116	22	AA082040	Human colon cancer
20	23	100.0	124	21	AA082040	Arabidopsis thalia
21	23	100.0	125	21	AA082040	Arabidopsis thalia
22	23	100.0	134	22	AA082040	Propionibacterium
23	23	100.0	150	23	AA082040	Human ovarian anti
24	23	100.0	166	22	AA082040	Novel human diapo
25	23	100.0	173	21	AA082040	Arabidopsis thalia
26	23	100.0	173	21	AA082040	Arabidopsis thalia
27	23	100.0	183	21	AA082040	Arabidopsis thalia
28	23	100.0	185	21	AA082040	Arabidopsis thalia
29	23	100.0	188	22	AA082040	Propionibacterium
30	23	100.0	166	21	AA082040	Arabidopsis thalia
31	23	100.0	199	23	AA082040	Human ovarian anti
32	23	100.0	204	22	AA082040	Novel human diapo
33	23	100.0	209	21	AA082040	Human secreted pro
34	23	100.0	220	23	AA082040	Listeria monocytog
35	23	100.0	222	21	AA082040	Arabidopsis thalia
36	23	100.0	224	22	AA082040	Novel human diapo
37	23	100.0	239	22	AA082040	Human secreted pro
38	23	100.0	241	22	AA082040	Human protein sequ
39	23	100.0	245	22	AA082040	Novel human diapo
40	24	100.0	272	23	AA082040	Listeria monocytog
41	24	100.0	278	22	AA082040	S-adenosylmethioni
42	24	100.0	309	21	AA082040	Human secreted pro
43	24	100.0	337	23	AA082040	Novel human diapo
44	24	100.0	347	22	AA082040	Novel human diapo
45	24	100.0	348	22	AA082040	Proteophila melanog

## ALIGNMENTS

```

RESULT 1
AA082040
1: AA082040 standard, peptide, 5 AA
XX AA082040:
XX
XX
XX 13-JUN-2001 (first entry)
XX Human heprecceptor domain A binding peptide Eupr428.
XX Human heprecceptor, cytosolic, anti HIV; antibiotic;
XX heprecceptor, human response inducer, cefin, infectious diseases, cancer;
XX HIV related dementia.
XX Homo sapiens.
XX CB2354241-A.
XX
XX 21-MAR-2001.
XX
XX 17-SEP-1999; 99GB-0021881.
XX 17-SEP-1999; 99GB-0021881.
XX (HOLM/) HOLMS R D.
XX Holms RD;
XX WPI, 2061 293287/31.
XX Novel regulatory or unfolding peptides of errin that binds to
XX heprecceptor, useful for inducing immune response for treating
XX infectious diseases and cancer.

```



Best Local Similarity 100.0%; Pred. No. 21;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLRLQ 5  
| | | | |

Db 6 MLRLQ 10

# RESULT 4

AA082038  
ID AA082038 standard; peptide; 12 AA.

XX AC A082038;

XX DT 13-JUN-2001 (first entry)

XX DE Human heprecceptor domain A binding peptide kupe2132.

XX KW Human; heprecceptor, cytostatic, anti HIV, antibiotic;

XX KW neotropic; immune response inducer; HIV; infectious diseases; cancer;

XX KW HIV-related dementia.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT Modified-site ID /note "Optionally phosphorylated"

XX PN GH2354241 A.

XX PD 21-MAR-2001.

XX PF 17-SEP-1999; 99CH-0021881.

XX PR 17-SEP-1999; 99CH-0021881.

XX PA (HOLM) HOLMS R. D.

XX PI Holms RD;

XX DR WPI: 2001 293287/31

XX PT Novel regulatory or inhibiting peptides of ezrin that binds to  
PT heprecceptor, useful for inducing immune response for treating  
PT infectious diseases and cancer.

XX PS Claim 24; Page 36; 42pp; English.

XX CC The heprecceptor is a novel active site in human ezrin. Ezrin regulates  
CC the structure of the cortical cytoskeleton to control cell surface  
CC topology. The present invention relates to peptides. (See A082038 to  
CC A082038) that bind to heprecceptor with greater affinity than HRP. (See  
CC A082038). The heprecceptor binding peptides are useful for inducing  
CC immune response, and for treating infectious diseases, cancer and  
CC HIV-related dementia. The present peptide binds to domain A of the  
CC heprecceptor (A082038).

XX SQ Sequence 12 AA;

Query Match 100.0%; Score 23; DB 22; Length 12.  
Best Local Similarity 100.0%; Pred. No. 21;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0.

QY 1 MLRLQ 5  
| | | | |

Db 4 MLRLQ 8

# RESULT 5

AA081119  
ID AA081119 standard; peptide; 12 AA.

XX AC A081119;

XX DE 09-APR-2002 (first entry)

XX DE Integrin-antagonist peptide #26.

XX KW IgG Fc; anticoagulant; thrombolytic; cytostatic;

XX KW antiinflammatory; immunosuppressive; osteopathic; antagonist;

XX KW laminin; saw-scaled viper; echistatin; integrin; selectin; vinculin;

XX KW platelet aggregation; angiogenesis; tumour; inflammation;

XX KW autoimmune disease; rheumatoid arthritis; osteoporosis.

XX OS Synthetic.

XX XX WO200181377-A2.

XX XX 01-NOV-2001.

XX XX 23-APR-2001; 2001WO-US13069.

XX XX 21-APR-2000; 2000US-198919P.

XX XX 03-MAY-2000; 2000US-201394P.

XX PA (AMGR-) AMGR INC.

XX PI Felipe U, Kohno T, Lacey DL, Boone TC;

XX XX WPI: 2002-05205708.

XX CC Composition comprising integrin or adhesion antagonistic peptide and  
XX vehicle, useful for treating or preventing platelet aggregation, has a  
XX longer half-life than free peptide.

XX PS Claim 11; Page 19; 68pp; English.

XX CC The invention relates to a composition comprising an integrin/adhesion  
XX antagonistic peptide (I) and a vehicle e.g. IgG Fc. The peptides  
XX are based on laminin or saw-scaled viper echistatin and target integrin,  
XX selectin or vinculin. Also included are compounds of formula (Ia) and  
XX their multimers (X<sup>2</sup>)<sub>1</sub>-A-P<sub>1</sub>-(X<sup>2</sup>)<sub>2</sub>-b where:

XX P<sub>1</sub> = FC domain;

XX X<sup>2</sup> = 1 or 2; (L<sup>1</sup>)<sub>1</sub>-e-P<sub>1</sub>, (L<sup>1</sup>)<sub>2</sub>-e-P<sub>1</sub>-(L<sup>2</sup>)<sub>1</sub>-d-P<sub>2</sub>,

XX (L<sup>1</sup>)<sub>1</sub>-e-P<sub>1</sub>-(L<sup>2</sup>)<sub>1</sub>-d-P<sub>2</sub>-(L<sup>3</sup>)<sub>1</sub>-e-P<sub>3</sub> or

XX (L<sup>1</sup>)<sub>1</sub>-e-P<sub>1</sub>-(L<sup>2</sup>)<sub>1</sub>-d-P<sub>2</sub>-(L<sup>3</sup>)<sub>1</sub>-e-P<sub>3</sub>-(L<sup>4</sup>)<sub>1</sub>-P<sub>4</sub>;

XX P<sub>1</sub>-P<sub>4</sub> = same or different (I);

XX L<sup>1</sup>-L<sup>4</sup> = same or different linkers;

XX a-f = 0 or 1, provided at least one of a and b = 1,

XX a nucleic acid that encodes (Ia), an expression vector containing the

XX pharmaceutically active compound (B) by covalently linking at least one

XX FC domain to at least one amino acid sequence of a selected randomized

XX (C) and any of six random-related peptides (D). The compositions are

XX used prophylactically and therapeutically in the same way as (I), e.g. to

XX inhibit platelet aggregation or angiogenesis (tumours), or to treat

XX inflammation and autoimmune diseases (e.g. rheumatoid arthritis) and many

XX different forms of osteoporosis, also for diagnosis. Attaching the

XX vehicle (especially FC domain) to (I) increases the half-life (I) and

XX are normally degraded very quickly in vivo. The present sequence

XX is an antagonist peptide of the invention.

XX SQ Sequence 12 AA;

Query Match 100.0%; Score 23; DB 23; Length 12;  
Best Local Similarity 100.0%; Pred. No. 21;  
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0.

QY 1 MLRLQ 5

| | | | |

Db 6 MLRLQ 10

# RESULT 6

ABB72970  
ID ABB72970 standard; peptide; 12 AA.



XX Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;  
 KW antirheumatic; antiproliferative; cytostatic; cardiac; vasotropic;  
 KW cerebroprotective; neurotropic; neuroprotective; antibacterial; virucide;  
 KW fungicide; ophthalmological; gene therapy; autoimmune disease; infection;  
 KW hyperproliferative disorder; cardiovascular disorder; angiogenesis;  
 KW cerebrovascular disorder; nervous system disorder; ocular disorder;  
 KW wound healing; skin aging; food additive; preservative.  
 XX  
 OS Homo sapiens.  
 XX  
 XX W0200058468-A2.  
 XX  
 PD 05-OCT-2000.  
 XX  
 XX 22-MAR-2000; 2000W000007526.  
 XX  
 PR 26-MAR-1999; 990S-0126600.  
 PR 22-DEC-1999; 990S-0171550.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INT.  
 PA  
 XX Rosen CA, Ruben SM, Komatsu S et al.  
 PI WPI: 2000-611713/58.  
 DR  
 XX Nucleic acids encoding human secreted proteins, used to prevent, treat,  
 PI ameliorate, or diagnose conditions such as autoimmune disorders, skin  
 PI disorders and cancer -  
 XX  
 XX Disclosure; Page 367; 374pp; English.  
 PS  
 XX The polynucleotide sequences given in AAC69499 to AAC69445 encode the  
 CC human secreted proteins given in AAB38119 to AAB38165. AAB38166 to  
 CC AAB38201 represent human secreted polypeptide sequences and proteins  
 CC homologous to them, which are given in the exemplification of the present  
 CC invention. Human secreted proteins have activities based on the tissues  
 CC and cells the genes are expressed in. Examples of activities include:  
 CC immunosuppression, antiarthritic, antirheumatic, antiproliferative,  
 CC neuroprotective, antitubercular, virucide, fungicide, and  
 CC ophthalmological. The polynucleotides and polypeptides can be used to  
 CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,  
 CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used  
 CC in diagnosing a pathological condition or susceptibility to a  
 CC autoimmune diseases, hyperproliferative disorders, cardiovascular  
 CC disorders, cerebrovascular disorders, angiogenesis, nervous system  
 CC disorders, infections caused by bacteria, viruses and fungi and ocular  
 CC disorders. The polypeptides can also be used to aid wound healing and  
 CC epithelial cell proliferation, to prevent skin aging due to sunburn, to  
 CC maintain organs before transplantation, for supporting cell culture of  
 CC primary tissues, to regenerate tissues and in chemotaxis. The  
 CC polypeptides can also be used as a food additive or preservative to  
 CC increase or decrease storage capabilities. AAC69499 to AAC69498 and  
 CC AAB38118 represent sequences used in the exemplification of the present  
 CC invention.  
 XX  
 SQ Sequence 15 AA;  
 Query Match 100.0%; Score 24; DB 21; Length 15;  
 Best Local Similarity 100.0%; Prod No. 26;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MLRQ 5  
 DB 10 MLRQ 14  
 RESULT 9  
 AAB82020  
 ID AAB82020 standard; peptide: 34 AA.  
 XX

AAH82020;  
 AC  
 XX 13 JUN 2001 (first entry)  
 DE Human hepreceptor domain B.  
 DE Human hepreceptor domain B.  
 KW Human, hepreceptor domain B; cytostatic; anti-HIV; antibiotic;  
 KW neotrophic, immune response inducer, ezrin, infectious diseases, cancer;  
 KW HIV-related dementia.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT Modified-site 14  
 FT /note- "Optionally phosphorylated"  
 PN GB2354241-A.  
 PF 21-MAR-2001.  
 XX  
 XX 17-SEP-1999; 99GB-0021881.  
 XX 17-SEP-1999; 99GB-0021881.  
 XX (HOLM/) HOLMS R D.  
 FA  
 XX Holmes ED;  
 FT WPI: 2001-263287/31.  
 XX  
 XX Novel regulatory or unfolding peptides of ezrin that binds to  
 PI hepreceptor, useful for inducing immune response for treating  
 PI infectious diseases and cancer -  
 XX  
 XX Claim 5; Page 45; 42pp; English.  
 XX The present sequence is domain B of human hepreceptor of human ezrin. The  
 CC hepreceptor is a seven active site to human ezrin. Ezrin regulates the  
 CC structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AAB82021 to  
 CC AAB82041) that bind to hepreceptor with greater affinity than HEPI (see  
 CC AAB82046). The hepreceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and  
 CC HIV-related dementia. The present sequence assembles into two  
 CC anti-parallel helices with hepreceptor domain A (see AAB82019).  
 XX  
 SQ Sequence 34 AA;  
 Query Match 100.0%; Score 23; DB 22; Length 34;  
 Best Local Similarity 100.0%; Prod No. 57;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MLRQ 5  
 DB 8 MLRQ 12  
 RESULT 10  
 AAB87003  
 ID AAB87003 standard; protein: 57 AA.  
 AC  
 XX AAB87003;  
 XX  
 XX 07-NOV-2001 (first entry)  
 DE Human immune/hematopoietic antigen SEQ ID NO:14596.  
 DE Human; immune; hematopoietic, immune/hematopoietic antigen; cancer;  
 KW cytostatic; gene therapy; vaccine, metastasis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W0200157182-A2.



DR WPI: 2001 183126/52.  
 XX N-PSDB: AAK59784.  
 PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
 PT useful for preventing, diagnosing and/or treating cancers and  
 PT metastasis.  
 PS Claim 11: SEQ ID NO 14596, 3071pp + Sequence Listing, English.  
 XX AAK54951 to AAK54962 encode the human immune/hematopoietic antigen (I)  
 CC amino acid sequences given in AAK54951 to AAK54962. (I) have cytostatic  
 CC activity, and can be used in gene therapy and vaccine production. (I)  
 CC proteins and polynucleotides may be used in the prevention, diagnosis and  
 CC treatment of diseases associated with inappropriate (I) expression. For  
 CC example, they may be used to treat disorders associated with decreased  
 CC expression by rectifying mutations or deletions in a patient's genome  
 CC that affect the activity of (I) by expressing inactive proteins or to  
 CC supplement the patient's own production of (I). Additionally, (I)  
 CC polynucleotides may be used to produce the secreted (I), by inserting  
 CC the nucleic acids into a host cell and culturing the cell to express the  
 CC protein. (I) proteins and polynucleotides may be used to prevent,  
 CC diagnose and treat immune/hematopoietic-related diseases, especially  
 CC cancers and cancer metastases of hematopoietic-derived cells. AAK54964  
 CC to AAK54969 represent human immune/hematopoietic antigen genomic  
 CC sequences from the present invention. AAK54942 to AAK54949 and AAK54959  
 CC represent sequences used in the exemplification of the present invention.  
 XX  
 SQ Sequence 57 AA;

Query Match 100.0%; Score 23; DB 22; Length 57;  
 Best Local Similarity 100.0%; Pred. No. 95;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLRLQ 5  
 II III  
 DB 7 MLRLQ 11

# RESULT 11

ID AA006711 standard; Protein: 73 AA.

XX AAC06711;

XX 06-NOV-2001 (first entry)

XX Human polypeptide SEQ ID NO 20603.

XX Human, cytokine, cell proliferation, cell differentiation; gene therapy;  
 KW vaccine, peptide therapy, stem cell growth factor, hematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorders; arthritis; inflammation.

XX Homo sapiens.

XX W02001164835-A2

XX 07-SEP-2001.

XX 26-FEB-2001; 2001WO-0504927

XX 28-FEB-2000; 2000US-0515326

XX 19-MAY-2000; 2000US-0577400

XX (HYSE-) HYSEQ INC.

XX Tang YF, Liu C, Drmanac RB;

XX WPI: 2001-514848/56

XX N-PSDB: AAI86642.

XX Isolated nucleic acids and polypeptides, useful for preventing  
 PT diagnosing and treating e.g. leukaemia, inflammation and immune

PT disorders -  
 XX  
 PS Claim 20: SEQ ID NO 20603; 1599pp + Sequence Listing; English.  
 XX The invention relates to human polynucleotides (AA170041-AA193841) and  
 CC the encoded proteins (AA00010-AA013910) that exhibit activity relating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth, factor activity, hematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activity, tumor activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pat\_sequences.

XX SQ Sequence 73 AA;

Query Match 100.0%; Score 24; DB 22; Length 73;  
 Best Local Similarity 100.0%; Pred. No. 125; 02;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLRLQ 5  
 II III  
 DB 68 MLRLQ 72

# RESULT 12

ID AB010135 standard; Protein: 82 AA.

XX AB010135;

XX 10-JAN-2002 (first entry)

XX Human cDNA SEQ ID NO: 443.

XX Human; gene therapy; neural disorder; immune system disorder;  
 KW muscular disorder; reproductive disorder; gastrointestinal disorder;  
 KW pulmonary disorder; cardiovascular disorder; renal disorder;  
 KW proliferative disorder; inflammation.

XX Homo sapiens.

XX W02001164474-A2

XX 02-AUG-2001.

XX 17-JAN-2001; 2001WO-0501349.

XX 31-JAN-2000; 2000US-179055P.

XX 04-FEB-2000; 2000US-180628P.

XX 24-FEB-2000; 2000US-181644P.

XX 02-MAR-2000; 2000US-186350P.

XX 16-MAR-2000; 2000US-189874P.

XX 17-MAR-2000; 2000US-190076P.

XX 18-APR-2000; 2000US-198124P.

XX 19-MAY-2000; 2000US-205515P.

XX 07-JUN-2000; 2000US-209457P.

XX 28-JUN-2000; 2000US-214886P.

XX 30-JUN-2000; 2000US-215135P.

XX 07-JUL-2000; 2000US-216647P.

XX 07-JUL-2000; 2000US-216880P.

XX 11-JUL-2000; 2000US-217487P.

XX 11-JUL-2000; 2000US-217496P.

XX 14-JUL-2000; 2000US-218290P.

XX 26-JUL-2000; 2000US-220963P.

XX 26-JUL-2000; 2000US-220964P.

XX 14-AUG-2000; 2000US-224518P.

XX 14-AUG-2000; 2000US-224519P.





RESULT 13  
 AAG03845  
 ID AAG03845 standard; Protein: 109 AA.  
 XX  
 AC AAG03845;  
 DT 06-OCT-2000 (first entry)  
 DE Human secreted protein, SEQ ID NO. 7926.  
 KW Human, 5' EST; expressed sequence tag; secreted protein; cDNA isolation;  
 KW gene therapy; chromosome mapping.  
 XX Homo sapiens.  
 XX EPI033401-A2.  
 XX 06-SEP-2000.  
 XX 21-FEB-2000; 2000HP-0200910  
 XX 26-FEB-1999; 9905-0122427.  
 XX (GSEST ) GENSET.  
 XX Dumas Milne Edwards J, Duclert A, Giordano J;  
 WP1: 2000-500381/45.  
 N-PSDB; AAG03851.  
 XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for  
 PT obtaining cDNAs and genomic DNAs that correspond to 5' ESTs and for  
 PT diagnostic, forensic, gene therapy and chromosome mapping procedures.  
 XX Claim 13; SEQ ID 7926, 71pp. + CD-ROM, English  
 XX The present sequence is a polypeptide encoded by one of a large number  
 CC of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs  
 CC were prepared from total human RNAs or polyA<sup>+</sup> RNAs derived from 30  
 CC different tissues. EST sequences usually correspond mainly to the 3'  
 CC untranslated region (UTR) of the mRNA because they are often obtained  
 CC from oligo-dT primed cDNA libraries. Such ESTs are not well suited for  
 CC isolating cDNA sequences derived from the 5' ends of mRNAs and even in  
 CC those cases where longer cDNA sequences have been obtained, the full 5'  
 CC UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5'  
 CC ends and can therefore be used to obtain full length cDNAs and genomic  
 CC DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and  
 CC chromosome mapping procedures. They are used to obtain upstream  
 CC regulatory sequences and to design expression and secretion vectors.  
 XX Sequence 109 AA;  
 SQ  
 Query Match: 100.0%; Score 23; 26 23; Length: 109;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MLRLQ 5  
 Db 21 MLRLQ 25  
 RESULT 14  
 AAG28299  
 ID AAG28299 standard; Protein: 111 AA.  
 XX  
 AC AAG28299;  
 XX  
 DT 18-FEB-2000 (first entry)  
 DE Novel human diagnostic protein #28290.  
 XX Human; chromosome mapping; gene mapping; gene therapy; forensic.  
 KW

food supplement; medical imaging; diagnostic; genetic disorder.  
 XX Homo sapiens.  
 XX WO200175067-A2.  
 XX 11-OCT-2001.  
 XX 30-MAR-2001; 2001WO-US08631.  
 XX 31-MAR-2000; 2000US-0540217.  
 XX 24-AUG-2000; 2000US-0649167.  
 XX (HYSE-) HYSEQ INC.  
 XX Brmanac RT, Liu C, Tang YI;  
 WP1: 2001-639362/73.  
 N-PSDB; AAS92486.  
 XX New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.  
 XX Claim 20; SEQ ID No 58658; 103pp; English.  
 XX The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC the polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. AAG03845-AAG03877 represent novel human  
 CC diagnostic amino acid sequences of the invention.  
 CC Note: the sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at [http://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences).  
 XX Sequence 111 AA;  
 SQ  
 Query Match: 100.0%; Score 23; 28 22; Length: 111;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MLRLQ 5  
 Db 7 MLRLQ 11  
 RESULT 15  
 AAG23000  
 ID AAG23000 standard; Protein: 114 AA.  
 XX  
 AC AAG23000;  
 XX 17-OCT-2000 (first entry)  
 XX Arabidopsis thaliana protein fragment SEQ ID No. 26142.  
 XX Protein identification, signal transduction pathway; metabolic pathway;  
 KW hybridisation assay; genetic mapping; gene expression control; promoter;  
 KW termination sequence.

XX	XX	29-JUN-1999;	990S-0140991.
OS	PR	PR	990S-0141297.
XX	PR	PR	990S-0141842.
XX	PR	PR	990S-0142154.
XX	PR	PR	990S-0142055.
XX	PR	PR	990S-0142390.
XX	PR	PR	990S-0142803.
XX	PR	PR	990S-0142920.
XX	PR	PR	990S-0142977.
XX	PR	PR	990S-0143424.
XX	PR	PR	990S-0143624.
XX	PR	PR	990S-0144005.
XX	PR	PR	990S-0144085.
XX	PR	PR	990S-0144086.
XX	PR	PR	990S-0144325.
XX	PR	PR	990S-0144331.
XX	PR	PR	990S-0144332.
XX	PR	PR	990S-0144333.
XX	PR	PR	990S-0144334.
XX	PR	PR	990S-0144335.
XX	PR	PR	990S-0144352.
XX	PR	PR	990S-0144632.
XX	PR	PR	990S-0144884.
XX	PR	PR	990S-0144814.
XX	PR	PR	990S-0145086.
XX	PR	PR	990S-0145088.
XX	PR	PR	990S-0145085.
XX	PR	PR	990S-0145087.
XX	PR	PR	990S-0145089.
XX	PR	PR	990S-0145192.
XX	PR	PR	990S-0145195.
XX	PR	PR	990S-0145218.
XX	PR	PR	990S-0145224.
XX	PR	PR	990S-0145276.
XX	PR	PR	990S-0145913.
XX	PR	PR	990S-0145918.
XX	PR	PR	990S-0145919.
XX	PR	PR	990S-0145951.
XX	PR	PR	990S-0146386.
XX	PR	PR	990S-0146388.
XX	PR	PR	990S-0146389.
XX	PR	PR	990S-0147038.
XX	PR	PR	990S-0147204.
XX	PR	PR	990S-0147302.
XX	PR	PR	990S-0147192.
XX	PR	PR	990S-0147260.
XX	PR	PR	990S-0147303.
XX	PR	PR	990S-0147416.
XX	PR	PR	990S-0147493.
XX	PR	PR	990S-0147935.
XX	PR	PR	990S-0148171.
XX	PR	PR	990S-0148319.
XX	PR	PR	990S-0148341.
XX	PR	PR	990S-0148555.
XX	PR	PR	990S-0148684.
XX	PR	PR	990S-0149368.
XX	PR	PR	990S-0149175.
XX	PR	PR	990S-0149426.
XX	PR	PR	990S-0149722.
XX	PR	PR	990S-0149723.
XX	PR	PR	990S-0149929.
XX	PR	PR	990S-0149902.
XX	PR	PR	990S-0149930.
XX	PR	PR	990S-0150566.
XX	PR	PR	990S-0150884.
XX	PR	PR	990S-0151065.
XX	PR	PR	990S-0151066.
XX	PR	PR	990S-0151080.
XX	PR	PR	990S-0151303.
XX	PR	PR	990S-0151438.
XX	PR	PR	990S-0151930.
XX	PR	PR	990S-0152363.
XX	PR	PR	990S-0153070.

PR 13-SEP-1999; 990S-0153758.  
 PR 15-SEP-1999; 990S-0154018.  
 PR 16-SEP-1999; 990S-0154039.  
 PR 20-SEP-1999; 990S-0154779.  
 PR 22-SEP-1999; 990S-0155139.  
 PR 23-SEP-1999; 990S-0155486.  
 PR 24-SEP-1999; 990S-0155659.  
 PR 28-SEP-1999; 990S-0156458.  
 PR 29-SEP-1999; 990S-0156596.  
 PR 04-OCT-1999; 990S-0157117.  
 PR 05-OCT-1999; 990S-0157753.  
 PR 06-OCT-1999; 990S-0157865.  
 PR 07-OCT-1999; 990S-0158029.  
 PR 08-OCT-1999; 990S-0158232.  
 PR 12-OCT-1999; 990S-0158369.  
 PR 13-OCT-1999; 990S-0159293.  
 PR 13-OCT-1999; 990S-0159294.  
 PR 13-OCT-1999; 990S-0159295.  
 PR 14-OCT-1999; 990S-0159329.  
 PR 14-OCT-1999; 990S-0159330.  
 PR 14-OCT-1999; 990S-0159331.  
 PR 14-OCT-1999; 990S-0159637.  
 PR 14-OCT-1999; 990S-0159638.  
 PR 18-OCT-1999; 990S-0159584.  
 PR 21-OCT-1999; 990S-0160741.  
 PR 21-OCT-1999; 990S-0160767.  
 PR 21-OCT-1999; 990S-0160768.  
 PR 21-OCT-1999; 990S-0160770.  
 PR 21-OCT-1999; 990S-0160814.  
 PR 21-OCT-1999; 990S-0160815.  
 PR 22-OCT-1999; 990S-0160980.  
 PR 22-OCT-1999; 990S-0160981.  
 PR 22-OCT-1999; 990S-0160984.  
 PR 25-OCT-1999; 990S-0161404.  
 PR 25-OCT-1999; 990S-0161405.  
 PR 25-OCT-1999; 990S-0161406.  
 PR 26-OCT-1999; 990S-0161459.  
 PR 26-OCT-1999; 990S-0161460.  
 PR 26-OCT-1999; 990S-0161461.  
 PR 28-OCT-1999; 990S-0161920.  
 PR 28-OCT-1999; 990S-0161992.  
 PR 28-OCT-1999; 990S-0161993.  
 PR 29-OCT-1999; 990S-0162142.

Query Match 100.0%; Score 23; DH 21; Length 114;  
 Best Local Similarity 100.0%; Pred. NO. 1.9e+02;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLRLQ 5  
 Db 32 MLRLQ 36

Search completed: January 16, 2003, 16:49:16  
 Job time : 24.7857 secs

